Carcinoma, Renal Cell: all 1,992 studies

Page 8 of 20. Open to participants first (387), then studies with results posted, then the rest; newest registration first within each.

• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell CarcinomaCompletedNCT00720941Phase 3Results posted
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerCompletedNCT00719264Phase 2Results posted
• Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)CompletedNCT00716625Results posted
• A Study for Participants With Metastatic Renal Cell CarcinomaCompletedNCT00709995Phase 2Results posted
• Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell CarcinomaCompletedNCT00706706Phase 4Results posted
• Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]CompletedNCT00700258Results posted
• Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell TransplantationTerminatedNCT00698685Phase 2Results posted
• Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor ResponseCompletedNCT00694096Phase 1Results posted
• RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in EuropeCompletedNCT00688753Phase 2Results posted
• Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00684996Phase 1/2Results posted
• Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®CompletedNCT00684645Results posted
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell CancerCompletedNCT00678392Phase 3Results posted
• A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.TerminatedNCT00678288Phase 2Results posted
• Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)TerminatedNCT00672178Phase 1/2Results posted
• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic CancerTerminatedNCT00670748Phase 2Results posted
• A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCCCompletedNCT00664326Phase 2Results posted
• Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)TerminatedNCT00651482Phase 2Results posted
• Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma SubjectsCompletedNCT00631371Phase 3Results posted
• Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell CarcinomaCompletedNCT00630409Phase 2Results posted
• Sorafenib Dose Escalation in Renal Cell CarcinomaCompletedNCT00618982Phase 2Results posted
• Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-AntibodyCompletedNCT00606632Phase 3Results posted
• Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00601926Phase 2Results posted
• PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00589550Phase 1Results posted
• Long-term Extension From RCC Phase II (11515)CompletedNCT00586495Phase 2Results posted
• Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)CompletedNCT00586105Phase 3Results posted
• Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney CancerTerminatedNCT00582790Phase 2Results posted
• Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)CompletedNCT00569946Phase 2Results posted
• Phase II Study of Vandetanib in Individuals With Kidney CancerCompletedNCT00566995Phase 2Results posted
• Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell CarcinomaTerminatedNCT00561912Phase 2Results posted
• Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell CarcinomaTerminatedNCT00557830Phase 2Results posted
• Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell CarcinomaCompletedNCT00556049Phase 2Results posted
• The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell CarcinomaCompletedNCT00554515Phase 2Results posted
• LBH589 Treatment for Refractory Clear Cell Renal CarcinomaCompletedNCT00550277Phase 2Results posted
• Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRICompletedNCT00537056Not applicableResults posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell CancerCompletedNCT00529802Phase 2Results posted
• A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell CarcinomaTerminatedNCT00523640Phase 2Results posted
• Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell CarcinomaTerminatedNCT00520533Phase 1Results posted
• A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.CompletedNCT00520403Phase 2Results posted
• A Study of Ramucirumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT00515697Phase 2Results posted
• A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaCompletedNCT00502307Phase 2Results posted
• Sorafenib in Treating Patients With Metastatic or Unresectable Kidney CancerTerminatedNCT00496756Phase 2Results posted
• Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell CarcinomaCompletedNCT00496587Phase 2Results posted
• Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell CarcinomaCompletedNCT00494091Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)TerminatedNCT00491738Phase 2Results posted
• Pemetrexed Plus Gemcitabine in Renal Cell CancerTerminatedNCT00491075Phase 2Results posted
• Zoledronate With Atorvastatin in Renal Cell CarcinomaCompletedNCT00490698Phase 2Results posted
• Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line SunitinibCompletedNCT00474786Phase 3Results posted
• Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00467077Phase 2Results posted
• Sunitinib Malate in Patients With Non-Clear Cell Renal Cell CancerCompletedNCT00465179Phase 2Results posted
• Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or MelanomaCompletedNCT00462982Phase 2Results posted
• SUTENT® In The First Line Treatment Of Renal Cell CarcinomaCompletedNCT00460798Results posted
• Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by SurgeryCompletedNCT00459979Phase 2Results posted
• Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney CancerCompletedNCT00459875Phase 2Results posted
• High-dose Bevacizumab in Advanced Renal Carcinoma PatientsCompletedNCT00455975Phase 2Results posted
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results posted
• Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT00429026Phase 2Results posted
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.CompletedNCT00428220Not applicableResults posted
• Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00425386Phase 2Results posted
• Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell CarcinomaCompletedNCT00423332Phase 2Results posted
• Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic MelanomaCompletedNCT00414765Phase 4Results posted
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or SunitinibCompletedNCT00410124Phase 3Results posted
• Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney CancerCompletedNCT00408902Phase 2Results posted
• Lenalidomide in Treating Patients With Advanced or Unresectable Kidney CancerCompletedNCT00403169Phase 2Results posted
• Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney CancerCompletedNCT00392821Phase 1/2Results posted
• Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell CancerCompletedNCT00387764Phase 3Results posted
• Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney CancerCompletedNCT00378703Phase 2Results posted
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.CompletedNCT00378482Phase 2Results posted
• Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00357760Phase 2Results posted
• Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell CarcinomaCompletedNCT00353301Phase 2Results posted
• Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney CancerCompletedNCT00338884Phase 2Results posted
• Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney TumorsCompletedNCT00335556Phase 2Results posted
• Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell CarcinomaCompletedNCT00334282Phase 3Results posted
• Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00331409Phase 2Results posted
• Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to FollowTerminatedNCT00330564Phase 2Results posted
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By SurgeryCompletedNCT00326898Phase 3Results posted
• Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00324870Phase 1/2Results posted
• Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney CancerTerminatedNCT00324740Phase 1/2Results posted
• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal CarcinomaCompletedNCT00323739Phase 2Results posted
• AZD2171 in Treating Patients With Refractory Metastatic Kidney CancerTerminatedNCT00303862Phase 2Results posted
• Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell CancerCompletedNCT00282048Phase 2Results posted
• Vorinostat in Treating Patients With Kidney CancerCompletedNCT00278395Phase 2Results posted
• Bortezomib in Treating Patients With Metastatic Kidney CancerCompletedNCT00276614Phase 2Results posted
• Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)CompletedNCT00267748Phase 2Results posted
• Study of SU011248 in Patients With Advanced Kidney CancerCompletedNCT00254540Phase 2Results posted
• GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell CarcinomaCompletedNCT00244764Phase 2Results posted
• Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00227760Phase 2Results posted
• Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.CompletedNCT00199888Phase 1Results posted
• Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250CompletedNCT00199875Phase 1Results posted
• Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell CarcinomaCompletedNCT00193258Phase 1/2Results posted
• Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney CancerTerminatedNCT00176501Phase 2Results posted
• Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal CancerCompletedNCT00142415Phase 1/2Results posted
• Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell CancerCompletedNCT00137423Phase 2Results posted
• Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney CancerTerminatedNCT00126659Phase 2Results posted
• Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney CancerCompletedNCT00126594Phase 2Results posted
• Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney CancerCompletedNCT00126503Phase 1/2Results posted
• Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00126490Phase 2Results posted
• Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney CancerCompletedNCT00121251Phase 1/2Results posted
• BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell CarcinomaCompletedNCT00117637Phase 2Results posted
• Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell CarcinomaCompletedNCT00113529Phase 1/2Results posted

← Carcinoma, Renal Cell overview